SynaptixBio

Activities: Research & Development

Trending Articles

  1. 25 Years of Guardtech – a new era for cleanroom furniture & equipment fit-outs with Guardware Suffolk-based cleanroom construction specialists the Guardtech Group have launched a new cleanroom furniture & equipment website to take their Guardware Cleanroom Hardware...
  2. ACG at Pharma Pro&Pack 2025 ACG to showcase world-class machinery, inspection systems, and process optimisation at Pharma Pro&Pack 2025
  3. Hovione and Microinnova team up to advance modular flow chemistry for multi-purpose manufacturing The modular approach will enable faster process transfer, sustainable operations and fully integrated development solutions
  4. EyeC ushers in a new era of quality control Pre-trained AI for intelligent inline inspection
  5. CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction...

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

Related Content

Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Research & Development

SynaptixBio selects H-ABC antisense oligonucleotide for clinical progression

The company will assess the safety and efficacy of SB H-19642 for the treatment of Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC)
Research & Development

SynaptixBio and Evotec collaborate to develop novel antisense oligonucelotides for H-ABC

The companies will look to discover novel antisense oligonucleotides targeting mutant TUBB4A for the treatment of H-ABC

SynaptixBio awarded FDA Orphan Drug Designation

SynaptixBio are now aiming to develop a treatment for the second variant of TUBB4A leukodystrophy
Research & Development

Biotech company awarded prestigious Innovate UK grant to expand search for rare disease therapies

SynaptixBio, the only company developing a treatment for a rare but deadly disease, will receive almost half a million pounds from the UK’s national innovation agency
Subscribe now